Multiple sclerosis and primary vascular dysregulation (Flammer syndrome)

EPMA Journal

Volumn 7, Issue 1, 2016, Pages

  Konieczka, Katarzyna ^a   Koch, Simone ^a   Binggeli, Tatjana ^a   Schoetzau, Andreas ^a   Kesselring, Juerg ^b  

^a UNIVERSITY OF BASEL   (Switzerland)

^b Rehabilitation Centre Valens   (Switzerland)

Author keywords

Flammer syndrome (FS); Multiple sclerosis (MS); Personalized medicine; Predictive diagnostics; Primary vascular dysregulation (PVD); Questionnaire; Targeted prevention

Indexed keywords

ADULT; AGED; ARTICLE; BODY MASS; CLINICAL FEATURE; COLD CLAMMY SKIN; CONTROLLED STUDY; DISEASE ASSOCIATION; DIZZINESS; DRUG RESPONSE; FEMALE; HEADACHE; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MULTIPLE SCLEROSIS; NOCICEPTION; OLFACTORY DISCRIMINATION; PRIMARY VASCULAR DYSREGULATION; PRIORITY JOURNAL; QUESTIONNAIRE; SKIN MANIFESTATION; SLEEP TIME; TINNITUS; VASCULAR DISEASE;

EID: 84974539677     PISSN: 18785077     EISSN: 18785085     Source Type: Journal    
DOI: 10.1186/s13167-016-0062-6     Document Type: Article

References (51)

1. Ransohoff RM, Hafler DA, Lucchinetti CF. Multiple sclerosis-a quiet revolution. Nat Rev Neurol. 2015;11(3):134-42.
2. Dorr J, Paul F. The transition from first-line to second-line therapy in multiple sclerosis. Curr Treat Options Neurol. 2015;17(6):354.
3. Kesselring J. History of multiple sclerosis. In: Raine C, McFarland HF, Hohlfeld R, editors. Multiple sclerosis-a comprehensive text. Chapter 1. Edinburgh, London, New York, Oxford, Philadelphia, St. Louis, Sydney, Toronto: Saunders Elsevier; Crown House Pub. Ltd.; 2008. p. 1-9.
4. Dake MD, Zivadinov R, Haacke EM. Chronic cerebrospinal venous insufficiency in multiple sclerosis: a historical perspective. Funct Neurol. 2011;26(4):181-95.
5. Ramagopalan SV, Dobson R, Meier UC, Giovannoni G. Multiple sclerosis: risk factors, prodromes, and potential causal pathways. Lancet Neurol. 2010;9(7):727-39.
6. Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372(9648):1502-17.
7. Lassmann H, Bruck W, Lucchinetti CF. The immunopathology of multiple sclerosis: an overview. Brain Pathol. 2007;17(2):210-8.
8. Marrie RA, Reider N, Cohen J, Stuve O, Trojano M, Cutter G, et al. A systematic review of the incidence and prevalence of cardiac, cerebrovascular, and peripheral vascular disease in multiple sclerosis. Mult Scler. 2015;21(3):318-31.
9. Jiang H, Delgado S, Tan J, Liu C, Rammohan KW, DeBuc DC, et al. Impaired retinal microcirculation in multiple sclerosis. Mult Scler. 2016. doi: 10.1177/1352458516631035.
10. Esen E, Sizmaz S, Demir T, Demirkiran M, Unal I, Demircan N. Evaluation of choroidal vascular changes in patients with multiple sclerosis using enhanced depth imaging optical coherence tomography. Ophthalmologica. 2016;235(2):65-71.
11. Karti O, Ayhan Z, Karahan E, Karti DT, Kaya M, et al. The evaluation of choroidal vascular changes associated with vascular dysregulation in patients with multiple sclerosis using enhanced depth imaging optical coherence tomography. J Clin Exp Ophthalmol. 2016;7:534.
12. Kemenyova P, Siarnik P, Sutovsky S, Blaho A, Turcani P, Kollar B. Impairment of endothelial function in patients with multiple sclerosis. Neuro Endocrinol Lett. 2015;36(1):67-71.
13. Flammer J, Konieczka K, Flammer AJ. The primary vascular dysregulation syndrome: implications for eye diseases. EPMA J. 2013;4(1):14.
14. Flammer J, Konieczka K, Bruno RM, Virdis A, Flammer AJ, Taddei S. The eye and the heart. Eur Heart J. 2013;34(17):1270-8.
15. Konieczka K, Ritch R, Traverso CE, Kim DM, Kook MS, Gallino A, et al. Flammer syndrome. EPMA J. 2014;5(1):11.
16. Flammer J, Orgul S, Costa VP, Orzalesi N, Krieglstein GK, Serra LM, et al. The impact of ocular blood flow in glaucoma. Prog Retin Eye Res. 2002;21(4):359-93.
17. Konieczka K, Frankl S, Todorova MG, Henrich PB. Unstable oxygen supply and glaucoma. Klin Monbl Augenheilkd. 2014;231(2):121-6.
18. Konieczka K, Flammer AJ, Todorova M, Meyer P, Flammer J. Retinitis pigmentosa and ocular blood flow. EPMA J. 2012;3(1):17.
19. Konieczka K, Koch S, Schoetzau A, Todorova MG. Increased prevalence of Flammer syndrome in patients with retinitis pigmentosa. Klin Monbl Augenheilkd. 2016;233(4):448-52.
20. Konieczka K, Choi HJ, Koch S, Schoetzau A, Kuenzi D, Kim DM. Frequency of symptoms and signs of primary vascular dysregulation in Swiss and Korean populations. Klin Monbl Augenheilkd. 2014;231(4):344-7.
21. Team RDC. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2012.
22. Mostafa BE, Kahky AO, Kader HM, Rizk M. Central vestibular dysfunction in an otorhinolaryngological vestibular unit: incidence and diagnostic strategy. Int Arch Otorhinolaryngol. 2014;18(3):235-8.
23. Tomaz A, Borges FN, Gananca CF, Campos CA, Tilbery CP. Signs and symptoms associated to otoneurologic alterations diagnosed on computerized vestibular exam of patients with multiple sclerosis. Arq Neuropsiquiatr. 2005;63(3B):837-42.
24. Hedstrom AK, Olsson T, Alfredsson L. Body mass index during adolescence, rather than childhood, is critical in determining MS risk. Mult Scler. 2016;22(7):878-83.
25. Kavak KS, Teter BE, Hagemeier J, Zakalik K, Weinstock-Guttman B, New York State Multiple Sclerosis C. Higher weight in adolescence and young adulthood is associated with an earlier age at multiple sclerosis onset. Mult Scler. 2015;21(7):858-65.
26. Kurz A, Sessler DI, Tayefeh F, Goldberger R. Poikilothermia syndrome. J Intern Med. 1998;244(5):431-6.
27. Besharat MA, Pourhosein R, Rostami R, Bazzazian S. Perfectionism and fatigue in multiple sclerosis. Psychol Health. 2011;26(4):419-32.
28. Speciale L, Sarasella M, Ruzzante S, Caputo D, Mancuso R, Calvo MG, et al. Endothelin and nitric oxide levels in cerebrospinal fluid of patients with multiple sclerosis. J Neurovirol. 2000;6 Suppl 2:S62-6.
29. Haufschild T, Shaw SG, Kesselring J, Flammer J. Increased endothelin-1 plasma levels in patients with multiple sclerosis. J Neuroophthalmol. 2001;21(1):37-8.
30. Stach BA, Delgado-Vilches G. Sudden hearing loss in multiple sclerosis: case report. J Am Acad Audiol. 1993;4(6):370-5.
31. La Mantia L, Prone V. Headache in multiple sclerosis and autoimmune disorders. Neurol Sci. 2015;36 Suppl 1:75-8.
32. Alroughani R, Ahmed SF, Khan R, Al-Hashel J. Status migrainosus as an initial presentation of multiple sclerosis. Springerplus. 2015;4:28.
33. Gelfand AA, Gelfand JM, Goadsby PJ. Migraine and multiple sclerosis: epidemiology and approach to treatment. Mult Scler Relat Disord. 2013;2(2):73-9.
34. Veauthier C, Paul F. Sleep disorders in multiple sclerosis and their relationship to fatigue. Sleep Med. 2014;15(1):5-14.
35. Veauthier C, Radbruch H, Gaede G, Pfueller CF, Dorr J, Bellmann-Strobl J, et al. Fatigue in multiple sclerosis is closely related to sleep disorders: a polysomnographic cross-sectional study. Mult Scler. 2011;17(5):613-22.
36. Growdon ME, Schultz AP, Dagley AS, Amariglio RE, Hedden T, Rentz DM, et al. Odor identification and Alzheimer disease biomarkers in clinically normal elderly. Neurology. 2015;84(21):2153-60.
37. Constantinescu CS, Raps EC, Cohen JA, West SE, Doty RL. Olfactory disturbances as the initial or most prominent symptom of multiple sclerosis. J Neurol Neurosurg Psychiatry. 1994;57(8):1011-2.
38. Dorr J, Doring A, Paul F. Can we prevent or treat multiple sclerosis by individualised vitamin D supply? EPMA J. 2013;4(1):4.
39. Rotstein DL, Healy BC, Malik MT, Carruthers RL, Musallam AJ, Kivisakk P, et al. Effect of vitamin D on MS activity by disease-modifying therapy class. Neurol Neuroimmunol Neuroinflamm. 2015;2(6):e167.
40. Kochkorov A, Gugleta K, Kavroulaki D, Katamay R, Weier K, Mehling M, et al. Rigidity of retinal vessels in patients with multiple sclerosis. Klin Monbl Augenheilkd. 2009;226(4):276-9.
41. Oettli A, Gugleta K, Kochkorov A, Katamay R, Flammer J, Orgul S. Rigidity of retinal vessel in untreated eyes of normal tension primary open-angle glaucoma patients. J Glaucoma. 2011;20(5):303-6.
42. Teuchner B, Orgul S, Ulmer H, Haufschild T, Flammer J. Reduced thirst in patients with a vasospastic syndrome. Acta Ophthalmol Scand. 2004;82(6):738-40.
43. Oberwahrenbrock T, Schippling S, Ringelstein M, Kaufhold F, Zimmermann H, Keser N, et al. Retinal damage in multiple sclerosis disease subtypes measured by high-resolution optical coherence tomography. Mult Scler Int. 2012;2012:530305.
44. Brandt AU, Oberwahrenbrock T, Ringelstein M, Young KL, Tiede M, Hartung HP, et al. Primary retinal pathology in multiple sclerosis as detected by optical coherence tomography. Brain. 2011;134(Pt 11):e193. author reply e4.
45. Dorr J, Krautwald S, Wildemann B, Jarius S, Ringelstein M, Duning T, et al. Characteristics of Susac syndrome: a review of all reported cases. Nat Rev Neurol. 2013;9(6):307-16.
46. Dorr J, Radbruch H, Bock M, Wuerfel J, Bruggemann A, Wandinger KP, et al. Encephalopathy, visual disturbance and hearing loss-recognizing the symptoms of Susac syndrome. Nat Rev Neurol. 2009;5(12):683-8.
47. Flammer J, Kaiser H, Haufschild T. Susac syndrome: a vasospastic disorder? Eur J Ophthalmol. 2001;11(2):175-9.
48. D'Haeseleer M, Hostenbach S, Peeters I, Sankari SE, Nagels G, De Keyser J, et al. Cerebral hypoperfusion: a new pathophysiologic concept in multiple sclerosis? J Cereb Blood Flow Metab. 2015;35(9):1406-10.
49. Haider L. Inflammation, iron, energy failure, and oxidative stress in the pathogenesis of multiple sclerosis. Oxid Med Cell Longev. 2015;2015:725370.
50. Haider L, Fischer MT, Frischer JM, Bauer J, Hoftberger R, Botond G, et al. Oxidative damage in multiple sclerosis lesions. Brain. 2011;134(Pt 7):1914-24.
51. Gugleta K, Kochkorov A, Kavroulaki D, Katamay R, Weier K, Mehling M, et al. Retinal vessels in patients with multiple sclerosis: baseline diameter and response to flicker light stimulation. Klin Monbl Augenheilkd. 2009;226(4):272-5.